Analgesic efficacy of Nefopam in cancer pain: A randomized controlled study
- Conditions
- Cancer paincancer painnefopamefficacy
- Registration Number
- TCTR20181016001
- Lead Sponsor
- Ramathibodi hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
1. Patients aged 18-80 years
2. Patients who has moderate to severe cancer pain (numeric rating scale 4/10-10/10) who needs analgesics to control pain
3. Patients who is willing to enroll the study
1. Patients who cannot evaluate their pain into numeric rating scale
2. Patients who are not able to use IV-PCA machine
3. Patients who are allergic to intravenous morphine
4. Patients who are on chemotherapy or radiation therapy during study period
5. Patients who undergo an operation within one week
6. Patients with a history of convulsive disorder
7. Patients who are diagnosed ischemic heart disease
8. Patients who are taking MAOI within 30 days before study period
9. Pregnants or breast feeing patients
10. Patients who deny to enroll the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analgesic efficacy record data every 4 hours until completing 48 hours numeric rating scale and dose of opioids used
- Secondary Outcome Measures
Name Time Method Incidence of side effects from nefopam during 48 hours after starting intervention record incidence of side effects